A phase Ib study of abemaciclib in combination with pembrolizumab for patients (pts) with stage IV Kirsten rat sarcoma mutant (KRAS-mut) or squamous non-small cell lung cancer (NSCLC) (NCT02779751): Interim results.
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Centre Hospitalier Universitaire de Montpellier, Universitair Ziekenhuis Leuven, Hospital Universitario 12 De Octubre, IRCCS Ospedale San Raffaele, Centre Hospitalier Universitaire de Toulouse, Institut universitaire du cancer de Toulouse Oncopole, Massachusetts General Hospital, Dana-Farber Cancer Institute, Merck & Co., Inc., Rahway, NJ, USA (United States), Eli Lilly (United States), Highlands Oncology Group
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Eli Lilly and Company
OpenAlex ID: W3031971173